Stifel Starts Medline Inc (MDLN) at Buy

Stifel analyst Rick Wise initiates coverage on Medline Inc (NASDAQ: MDLN) with a Buy rating and a price target of $46.00.

The analyst comments: "Medline is the largest pureplay publicly-traded MedSurg product & distribution company. With a 58- year consistent annual growth track-record and a unique business model, roughly divided between med-surg distribution and MDLN-branded products, both businesses have driven and should continue driving HSD+ top-line growth. In 2025, we estimate Medline will generate $28.2B in sales (+9.5% Y/Y organic) along with 12.1% EBITDA margins. Looking ahead, we anticipate, potentially-conservatively, high-single-digit sales growth. Medline's growth and profitability engine is driven by a well-established, truly-compelling, and unique commercial model. The company leverages its impressively-scaled distribution and service advantage and steadily adds incremental customers, new prime vendor contracts (i.e. where MDLN serves as customers’ primary med-surg product distributor), and adjacent business lines. Then, over time, new customers are steadily-converted to Medline's own rapidly-expanding Medline Brand portfolio."

For an analyst ratings summary and ratings history on Medline Inc click here. For more ratings news on Medline Inc click here.

Shares of Medline Inc closed at $40.52 yesterday.

You May Also Be Interested In

• Carlyle to sell Copia Power to EQT - FT
• Goldman Sachs bans staff from prediction-market bets on finance, war - Bloomberg
• Pepsico (PEP) PT Lowered to $176 at Piper Sandler